|
Post by kc on Mar 19, 2018 22:54:14 GMT -5
They would not make any big announcement in this type of forum . This is more to expose themselves to institutional investors and their customers.
|
|
|
Post by kc on Mar 14, 2018 15:56:30 GMT -5
Staying long and I am needing a 10 step program for posting too much.
2922 postings. Now that is a person with too little to do.
|
|
|
Post by kc on Mar 13, 2018 20:40:58 GMT -5
The $4 is a signal that, "look, we think the stock will actually surpass $4 withing two years." Now, whether that "signal" is genuinely meant or not, I don't know. Mann Group is still waiting and wanting a big Pay Day payout one day. They have not walked away. They have patience to see it though to the end.
|
|
|
Post by kc on Mar 13, 2018 20:31:05 GMT -5
I think the study was completed in December, wasn’t it? I am ignorant on how studies work for presentations, but is it possible the study is under peer review so that it can be presented at the conference post peer review. Dennis you are correct that is why it’s embargoed until its presented in the ADA publication tied to the convention and published at the end. It’s the Dog & Pony show that the ADA puts on to draw people to their convention. It’s all good and we just have to let it play out.
|
|
|
Post by kc on Mar 10, 2018 13:00:44 GMT -5
Happened to see this article to day about Sanofi and their problem selling their wonder drug cholesterol-lowering drug Praluent. That is the same drug they had the lawsuit with Amgen on and lost. But if you read the article you will see that one of the issues that both Sanofi and Amgen have with the drug is the cost to the payer (insurer) Its way too high and they push back on letting patients receive it. So they have worked on a new Strategy to lower the price to the payer and create a more outcome based prescribing model.
"Now Regeneron and Sanofi are going one step further, agreeing to lower the price for Praluent to match an independent analysis that found it would be cost-effective for the highest-risk patients at a net cost of $4,500 to $8,000 a year. The companies added one condition to the lower price: that health insurers agree to remove the restrictions, like extensive tests and paperwork, that make prescribing the medicine an arduous process for doctors.
“We have to get the whole world to realize this is cost-effective for society and we have to get this drug to the patients who will benefit the most,” said George Yancopoulos, chief scientific officer at Tarrytown, New York-based Regeneron.
www.bloombergquint.com/business/2018/03/10/regeneron-sanofi-cut-heart-drug-s-price-as-trial-disappoints
This is probably the same direction that MannKind HAS to take to become a preferred Insulin product as the Healthcare industry is changing rapidly. I have to just wonder if Mike C knew this in hiring of Dr. David Kendall. MannKind has to work with payers to show Afrezza is the most cost effective Insulin product at either today's cost or a negotiated fixed price cost to the payer in order to gain critical mass. Remove restrictions and make it easier to prescribe Afrezza and we will give you more cost effective pricing. Perhaps a subscription based program.
Payers are adding the term OUTCOME BASED SOLUTIONS to their talking points and it evident as you see some of the recent marriages. CVS Buying Aetna Cigna Buy Express Scripts. Berkshire Hathaway/Amazon / JP Morgan Healthcare joint venture.
Payers want good outcomes for patients at a cheaper prices.
|
|
|
Post by kc on Mar 8, 2018 21:33:07 GMT -5
kc - does Robin use Afrezza? She is so busy I got tired just reading her bio ... Ha! Not that I know of, but MannKind should find a fitness person and get them engaged. Lots of young #T1D’s who need a good role model. she seems to be a hip type person. Would fit the demographic of the 20 to 40 year old wanting to take charge of their life and diabetes. The non-passive diabetic.
|
|
|
Post by kc on Mar 8, 2018 21:29:17 GMT -5
Asked and answered since the termination period. Need to end this thread and move on. Mod..... Pull the plug and lock it down.
|
|
|
Post by kc on Mar 8, 2018 11:36:36 GMT -5
Big Block trade at 11:05:41 didn't move the needle.... 132,900 shares.
Fidelity Raised the Borrow rate to 55%
Institutional ownership is also on the rise according to NASDAQ. Now 19.59% that is up from 12% low.
|
|
|
Post by kc on Mar 8, 2018 11:02:04 GMT -5
|
|
|
Post by kc on Mar 7, 2018 22:02:27 GMT -5
I'd be watching Laura, but if you cast a good-looking guy with her you might get the rest of the women (and the gay men) to also miss the warnings. Oh I got one! Both live in Atlanta so it would be cheap to do the production there with no travel expense. I think its meant to be for them both to be in the next commercial together. Is this going to be a company sanctioned commercial or should it be shareholder driven, produced and delivered at the May shareholders meeting?
|
|
|
Post by kc on Mar 2, 2018 21:32:26 GMT -5
I’m in Kansas and follow that yellow brick road everyday but have not found that Emerald city yet. Perhaps it Eudora KS.... or maybe it will be Leavenworth KS for Martin Shkreli.
|
|
|
Post by kc on Mar 1, 2018 13:14:41 GMT -5
Mike is a fighter. He needs Spencer in the room at the annual meeting just to release the inner Philadelphia street kid. He won't be at the annual meeting as he is not a shareholder. He is a paid shill.....
|
|
|
Post by kc on Mar 1, 2018 12:32:27 GMT -5
Yes it's about patient / Doctor education. That will be the job that David Kendall will have to help the marketing team with is Afrezza will give the payer better outcomes and a more cost effective treatment program if they give it a chance and take the time to learn about the benefits.
|
|
|
Post by kc on Mar 1, 2018 12:21:30 GMT -5
|
|
|
Post by kc on Feb 27, 2018 18:08:31 GMT -5
Unscheduled material affect was the call being cut off sharply at the top of the hour.
I hope that they figure out another way to deal with that before the next quarter.
Very disappointing
|
|